Ultragenyx Pharmaceutical Inc. (RARE) financial statements (2020 and earlier)

Company profile

Business Address 60 LEVERONI COURT
NOVATO, CA 94949
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments755460234380437187
Cash and cash equivalents4341131001619424
Short-term investments322346134219343163
Restricted cash and investments00010 
Receivables33135   
Inventory, net of allowances, customer advances and progress billings1271   
Inventory1271   
Other undisclosed current assets51432920136
Total current assets:851522270402450193
Noncurrent Assets
Operating lease, right-of-use asset30
Property, plant and equipment4420221773
Long-term investments and receivables5 1011899 
Long-term investments5 1011899 
Intangible assets, net (including goodwill)173174186   
Goodwill444444   
Intangible assets, net (excluding goodwill)129129142   
Restricted cash and investments2 2221
Other noncurrent assets341211
Other undisclosed noncurrent assets25     
Total noncurrent assets:2841972211391095
TOTAL ASSETS:1,135720491541560198
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities967570602817
Accounts payable13129535
Accrued liabilities83626155258
Employee-related liabilities     4
Debt7     
Deferred revenue and credits1000
Other undisclosed current liabilities     (4)
Total current liabilities:1037571602813
Noncurrent Liabilities
Long-term debt and lease obligation30     
Operating lease, liability30
Liabilities, other than long-term debt 3636611
Deferred tax liabilities, net3131   
Other liabilities 55611
Other undisclosed noncurrent liabilities349     
Total noncurrent liabilities:3783636611
Total liabilities:482111107672813
Stockholders' equity
Stockholders' equity attributable to parent654609383474531185
Common stock000000
Additional paid in capital2,0871,6401,2221,004817324
Accumulated other comprehensive income (loss)(0)(1)(6)1(1)(0)
Accumulated deficit(1,433)(1,030)(833)(531)(285)(139)
Total stockholders' equity:654609383474531185
TOTAL LIABILITIES AND EQUITY:1,135720491541560198

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues1045130  
Revenue, net30  
Cost of revenue
(Cost of Goods and Services Sold)
 (1)(0)   
Gross profit:1045030  
Operating expenses(528)(423)(332)(248)(148)(57)
Other undisclosed operating income 10   
Operating loss:(424)(371)(329)(248)(148)(57)
Nonoperating income (expense)1241122(3)
Investment income, nonoperating13104421
Other nonoperating income (expense)(1)(6)7(2)(0)(4)
Loss from continuing operations before equity method investments, income taxes:(412)(367)(318)(246)(146)(60)
Other undisclosed income from continuing operations before income taxes12170    
Loss from continuing operations before income taxes:(399)(197)(318)(246)(146)(60)
Income tax expense (benefit)(3)(1)16(0)  
Net loss attributable to parent:(403)(198)(302)(246)(146)(60)
Preferred stock dividends and other adjustments     (5)
Net loss available to common stockholders, diluted:(403)(198)(302)(246)(146)(65)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(403)(198)(302)(246)(146)(60)
Other comprehensive income (loss)05(7)2  
Comprehensive loss:(402)(193)(309)(244)(146)(60)
Other undisclosed comprehensive loss, net of tax, attributable to parent    (1)(0)
Comprehensive loss, net of tax, attributable to parent:(402)(193)(309)(244)(146)(60)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: